Right. So, February 17th, 2026. Another day, another portfolio tweak. Ananym Capital Management decided to lighten their position in Sotera Health (SHC 1.37%). Not a full-on exit, mind you. Just…a trim. A bit like deciding you need to stop eating quite so many biscuits. It’s not that biscuits are bad, exactly. It’s just that, well, one can only eat so many biscuits before one’s trousers start to feel… snug.
They sold 217,684 shares, apparently, for around $3.6 million. Which, in the grand scheme of things, isn’t a fortune. It’s roughly the cost of a small island, or a very large number of biscuits. The fund’s overall stake is now 8.65% – still a significant chunk, so let’s not panic. Not yet, anyway.
Here’s a quick list of what’s been happening, because lists are good. Lists bring order to chaos. I need order. I really do.
- Top Holdings (as of Feb 17th):
- NYSE:VAC: $42.51 million (17.5% of AUM)
- NASDAQ:HSIC: $41.35 million (17.0% of AUM)
- NASDAQ:BKR: $36.61 million (15.1% of AUM)
- NASDAQ:SCHL: $35.85 million (14.7% of AUM)
- NASDAQ:LKQ: $33.52 million (13.8% of AUM)
- Sotera Health Performance: Up nearly 30% over the past year. Outperforming the S&P 500 by 14.86 percentage points. (Which is nice. Very nice, indeed.)
Let’s look at the numbers, shall we? Because numbers are supposed to be reassuring. They rarely are, of course, but one can hope.
| Metric | Value |
|---|---|
| Revenue (TTM) | $1.16 billion |
| Net income (TTM) | $77.95 million |
| Price (as of market close 2/17/26) | $17.09 |
| One-year price change | 26.59% |
Sotera, for those who haven’t been paying attention (and honestly, who can blame you?), provides sterilization services – gamma, electron beam, EO processing – plus laboratory testing and advisory services. Basically, they make sure everything is clean and safe. Which is, when you think about it, a rather good business to be in. Especially in the current climate. One doesn’t want to dwell on what happens when things aren’t clean and safe.
They serve medical device manufacturers, pharmaceutical companies, and food/agricultural businesses. A diversified client base. Sensible. I should be more sensible.
So, what does this transaction mean? Honestly? Probably not much. It feels like a bit of risk management after a good run. A sensible trim, not a complete haircut. Sotera has delivered 20 consecutive years of revenue growth. Twenty! That’s…impressive. Net revenues rose nearly 6% to $1.16 billion in 2025, and adjusted EBITDA climbed 8% to $594 million. Net income nearly doubled to $78 million. And management is guiding for another 5% to 6.5% revenue increase in 2026. It’s…stable. Predictable. Boring, even. But sometimes, boring is good. Very good, indeed.
This isn’t some speculative biotech. It’s mission-critical infrastructure. Medical device and pharma companies can’t easily replace it. Cash flow is improving, leverage is falling, and liquidity is strengthening. It’s…solid. Like a well-made pair of shoes. Or a reliable biscuit.
Within a portfolio that also includes cyclical and industrial names, keeping Sotera as a top allocation preserves exposure to steady, regulated demand. Long-term investors should focus less on a $3.6 million trade and more on a business that’s been compounding revenue for two decades. A business where reliability is, quite literally, a matter of life and death.
Units of Cryptocurrency Lost: 12. Hours Spent Watching Charts: 9. Number of Panicked Texts to Friends: 24. Must…remain…disciplined. Must…focus…on…reliable…biscuits.
Read More
- Top 15 Insanely Popular Android Games
- Gold Rate Forecast
- Did Alan Cumming Reveal Comic-Accurate Costume for AVENGERS: DOOMSDAY?
- 4 Reasons to Buy Interactive Brokers Stock Like There’s No Tomorrow
- EUR UAH PREDICTION
- Silver Rate Forecast
- DOT PREDICTION. DOT cryptocurrency
- ELESTRALS AWAKENED Blends Mythology and POKÉMON (Exclusive Look)
- New ‘Donkey Kong’ Movie Reportedly in the Works with Possible Release Date
- Core Scientific’s Merger Meltdown: A Gogolian Tale
2026-03-02 16:52